Loading
Adding the anti-angiogenic antibody bevacizumab to chemotherapy lengthened survival by almost four months in recurrent or metastatic cervical cancer, the first targeted drug to improve survival in a gynaecological cancer.
Phase 3 factorial trial of 452 patients with recurrent, persistent or metastatic cervical cancer randomised to cisplatin-paclitaxel or topotecan-paclitaxel, with or without bevacizumab.
Median overall survival was 17.0 versus 13.3 months with bevacizumab (hazard ratio 0.71) and response 48 versus 36 percent; topotecan-paclitaxel was not superior to cisplatin-paclitaxel. Fistula occurred in about 6 percent of bevacizumab patients, mostly after prior radiotherapy.
Platinum-paclitaxel with bevacizumab became the first-line standard for advanced cervical cancer and remains the backbone to which pembrolizumab is added.
Shares Krishnansu S. Tewari, Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Recurrent or metastatic cervical cancer, Bevacizumab.
Shares Recurrent or metastatic cervical cancer, Bevacizumab.
Shares Recurrent or metastatic cervical cancer, Bevacizumab.
Shares Recurrent or metastatic cervical cancer, Bevacizumab.
Shares Recurrent or metastatic cervical cancer, Bevacizumab.